A TLR5 agonist enhances CD8+ T cell-mediated graft-versus-tumor effect without exacerbating graft-versus-host disease

Journal of Immunology

Volumn 189, Issue 10, 2012, Pages 4719-4727

  Ding, Xilai ^a   Bian, Guanglin ^a   Leigh, Nicholas D ^a   Qiu, Jingxin ^a   McCarthy, Philip L ^a   Liu, Hong ^a   Aygun Sunar, Semra ^a   Burdelya, Lyudmila G ^a   Gudkov, Andrei V ^a   Cao, Xuefang ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CBLB 502; CD11B ANTIGEN; GLYCOPROTEIN P 15095; IMMUNOMODULATING AGENT; INTERLEUKIN 12; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL POPULATION; CONTROLLED STUDY; DNA SEQUENCE; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; GRAFT VERSUS HOST REACTION; HISTOPATHOLOGY; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; TUMOR VOLUME;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; FLAGELLIN; GRAFT VS HOST DISEASE; GRAFT VS TUMOR EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNITY, CELLULAR; MICE; MICE, INBRED BALB C; MICE, INBRED DBA; NEOPLASMS, EXPERIMENTAL; SALMONELLA; TOLL-LIKE RECEPTOR 5; TRANSPLANTATION, HOMOLOGOUS;

EID: 84868588130     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1201206     Document Type: Article

References (45)

1. Kolb, H. J., C. Schmid, A. J. Barrett, and D. J. Schendel. 2004. Graft-versus-leukemia reactions in allogeneic chimeras. Blood 103: 767-776.
2. Horowitz, M. M., R. P. Gale, P. M. Sondel, J. M. Goldman, J. Kersey, H. J. Kolb, A. A. Rimm, O. Ringdén, C. Rozman, B. Speck, et al. 1990. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75: 555-562.
3. Weiden, P. L., N. Flournoy, E. D. Thomas, R. Prentice, A. Fefer, C. D. Buckner, and R. Storb. 1979. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N. Engl. J. Med. 300: 1068-1073.
4. Sinkovics, J. G. 2010. Antileukemia and antitumor effects of the graft-versus-host disease: a new immunovirological approach. Acta Microbiol. Immunol. Hung. 57: 253-347.
5. Rezvani, A. R., and R. F. Storb. 2008. Separation of graft-vs.-tumor effects from graft-vs.-host disease in allogeneic hematopoietic cell transplantation. J. Auto-immun. 30: 172-179.
6. Olson, J. A., D. B. Leveson-Gower, S. Gill, J. Baker, A. Beilhack, and R. S. Negrin. 2010. NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects. Blood 115: 4293-4301.
7. Ine, S., M. Yamada, K. Miyamura, and T. Sasaki. 2003. [Immunological mechanisms of graft versus tumor effect]. Nippon Rinsho 61: 1495-1502.
8. Zakrzewski, J. L., A. A. Kochman, S. X. Lu, T. H. Terwey, T. D. Kim, V. M. Hubbard, S. J. Muriglan, D. Suh, O. M. Smith, J. Grubin, et al. 2006. Adoptive transfer of T-cell precursors enhances T-cell reconstitution after allo-geneic hematopoietic stem cell transplantation. Nat. Med. 12: 1039-1047.
9. Hartmann, N., F. Leithäuser, C. Albers, J. Duyster, P. Möller, K. M. Debatin, and G. Strauss. 2011. In vitro-established alloantigen-specific CD8+ CTLs mediate graft-versus-tumor activity in the absence of graft-versus-host disease. Leukemia 25: 848-855.
10. Flutter, B., N. Edwards, F. Fallah-Arani, S. Henderson, J. G. Chai, S. Sivakumaran, S. Ghorashian, C. L. Bennett, G. J. Freeman, M. Sykes, and R. Chakraverty. 2010. Nonhematopoietic antigen blocks memory programming of alloreactive CD8+ T cells and drives their eventual exhaustion in mouse models of bone marrow transplantation. J. Clin. Invest. 120: 3855-3868.
11. Kanzler, H., F. J. Barrat, E. M. Hessel, and R. L. Coffman. 2007. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat. Med. 13: 552-559.
12. Yamamoto, M., and K. Takeda. 2010. Current views of toll-like receptor signaling pathways. Gastroenterol. Res. Pract. 2010: 240365.
13. Kim, J. Y., Y. J. Kim, J. S. Kim, H. S. Ryu, H. K. Lee, J. S. Kang, H. M. Kim, J. T. Hong, Y. Kim, and S. B. Han. 2011. Adjuvant effect of a natural TLR4 ligand on dendritic cell-based cancer immunotherapy. Cancer Lett. 313: 226-234.
14. Cheng, C., P. Jain, I. Bettahi, S. Pal, D. Tifrea, and L. M. de la Maza. 2011. A TLR2 agonist is a more effective adjuvant for a Chlamydia major outer membrane protein vaccine than ligands to other TLR and NOD receptors. Vaccine 29: 6641-6649.
15. Kwissa, M., H. I. Nakaya, H. Oluoch, and B. Pulendran. 2012. Distinct TLR adjuvants differentially stimulate systemic and local innate immune responses in nonhuman primates. Blood 119: 2044-2055.
16. Yoon, S. I., O. Kurnasov, V. Natarajan, M. Hong, A. V. Gudkov, A. L. Osterman, and I. A. Wilson. 2012. Structural basis of TLR5-flagellin recognition and signaling. Science 335: 859-864.
17. Vicente-Suarez, I., J. Brayer, A. Villagra, F. Cheng, and E. M. Sotomayor. 2009. TLR5 ligation by flagellin converts tolerogenic dendritic cells into activating antigen-presenting cells that preferentially induce T-helper 1 responses. Immunol. Lett. 125: 114-118.
18. Honko, A. N., N. Sriranganathan, C. J. Lees, and S. B. Mizel. 2006. Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis. Infect. Immun. 74: 1113-1120.
19. McSorley, S. J., B. D. Ehst, Y. Yu, and A. T. Gewirtz. 2002. Bacterial flagellin is an effective adjuvant for CD4+ T cells in vivo. J. Immunol. 169: 3914-3919.
20. +/+ CD11c+ cells is necessary for the adjuvant activity of flagellin. J. Immunol. 182: 7539-7547.
21. Cuadros, C., F. J. Lopez-Hernandez, A. L. Dominguez, M. McClelland, and J. Lustgarten. 2004. Flagellin fusion proteins as adjuvants or vaccines induce specific immune responses. Infect. Immun. 72: 2810-2816.
22. Huleatt, J. W., A. R. Jacobs, J. Tang, P. Desai, E. B. Kopp, Y. Huang, L. Song, V. Nakaar, and T. J. Powell. 2007. Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity. Vaccine 25: 763-775.
23. Datta, S. K., V. Redecke, K. R. Prilliman, K. Takabayashi, M. Corr, T. Tallant, J. DiDonato, R. Dziarski, S. Akira, S. P. Schoenberger, and E. Raz. 2003. A subset of Toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells. J. Immunol. 170: 4102-4110.
24. Bates, J. T., A. H. Graff, J. P. Phipps, J. M. Grayson, and S. B. Mizel. 2011. Enhanced antigen processing of flagellin fusion proteins promotes the antigen-specific CD8+ T cell response independently of TLR5 and MyD88. J. Immunol. 186: 6255-6262.
25. Arimilli, S., J. B. Johnson, K. M. Clark, A. H. Graff, M. A. Alexander-Miller, S. B. Mizel, and G. D. Parks. 2008. Engineered expression of the TLR5 ligand flagellin enhances paramyxovirus activation of human dendritic cell function. J. Virol. 82: 10975-10985.
26. Sfondrini, L., A. Rossini, D. Besusso, A. Merlo, E. Tagliabue, S. Mènard, and A. Balsari. 2006. Antitumor activity of the TLR-5 ligand flagellin in mouse models of cancer. J. Immunol. 176: 6624-6630.
27. Bohnhorst, J., T. Rasmussen, S. H. Moen, M. Fløttum, L. Knudsen, M. Børset, T. Espevik, and A. Sundan. 2006. Toll-like receptors mediate proliferation and survival of multiple myeloma cells. Leukemia 20: 1138-1144.
28. Cai, Z., A. Sanchez, Z. Shi, T. Zhang, M. Liu, and D. Zhang. 2011. Activation of Toll-like receptor 5 on breast cancer cells by flagellin suppresses cell proliferation and tumor growth. Cancer Res. 71: 2466-2475.
29. Burdelya, L. G., V. I. Krivokrysenko, T. C. Tallant, E. Strom, A. S. Gleiberman, D. Gupta, O. V. Kurnasov, F. L. Fort, A. L. Osterman, J. A. Didonato, et al. 2008. An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science 320: 226-230.
30. Fukuzawa, N., M. Petro, W. M. Baldwin, III, A. V. Gudkov, and R. L. Fairchild. 2011. A TLR5 agonist inhibits acute renal ischemic failure. J. Immunol. 187: 3831-3839.
31. Burdelya, L. G., A. S. Gleiberman, I. Toshkov, S. Aygun-Sunar, M. Bapardekar, P. Manderscheid-Kern, D. Bellnier, V. I. Krivokrysenko, E. Feinstein, and A. V. Gudkov. 2012. Toll-like receptor 5 agonist protects mice from dermatitis and oral mucositis caused by local radiation: implications for head-and-neck cancer radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 83: 228-234.
32. Cao, X., S. F. Cai, T. A. Fehniger, J. Song, L. I. Collins, D. R. Piwnica-Worms, and T. J. Ley. 2007. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity 27: 635-646.
33. Gross, S., and D. Piwnica-Worms. 2005. Real-time imaging of ligand-induced IKK activation in intact cells and in living mice. Nat. Methods 2: 607-614.
34. Cao, X., K. Leonard, L. I. Collins, S. F. Cai, J. C. Mayer, J. E. Payton, M. J. Walter, D. Piwnica-Worms, R. D. Schreiber, and T. J. Ley. 2009. Interleukin 12 stimulates IFN-gamma-mediated inhibition of tumor-induced regulatory T-cell proliferation and enhances tumor clearance. Cancer Res. 69: 8700-8709.
35. Cai, S. F., X. Cao, A. Hassan, T. A. Fehniger, and T. J. Ley. 2010. Granzyme B is not required for regulatory T cell-mediated suppression of graft-versus-host disease. Blood 115: 1669-1677.
36. Dutt, S., J. Baker, H. E. Kohrt, N. Kambham, M. Sanyal, R. S. Negrin, and S. Strober. 2011. CD8+CD44(hi) but not CD4+CD44(hi) memory T cells mediate potent graft antilymphoma activity without GVHD. Blood 117: 3230-3239.
37. Ortega-Cava, C. F., S. Ishihara, M. A. Rumi, M. M. Aziz, H. Kazumori, T. Yuki, Y. Mishima, I. Moriyama, C. Kadota, N. Oshima, et al. 2006. Epithelial toll-like receptor 5 is constitutively localized in the mouse cecum and exhibits distinctive down-regulation during experimental colitis. Clin. Vaccine Immunol. 13: 132-138.
38. Applequist, S. E., R. P. Wallin, and H. G. Ljunggren. 2002. Variable expression of Toll-like receptor in murine innate and adaptive immune cell lines. Int. Immunol. 14: 1065-1074.
39. Jiang, D., and H. Schwarz. 2010. Regulation of granulocyte and macrophage populations of murine bone marrow cells by G-CSF and CD137 protein. PLoS ONE 5: e15565.
40. Asavaroengchai, W., H. Wang, S. Wang, L. Wang, R. Bronson, M. Sykes, and Y. G. Yang. 2007. An essential role for IFN-gamma in regulation of alloreactive CD8 T cells following allogeneic hematopoietic cell transplantation. Biol. Blood Marrow Transplant. 13: 46-55.
41. Cooke, K. R., G. R. Hill, J. M. Crawford, D. Bungard, Y S. Brinson, J. Delmonte, Jr., and J. L. Ferrara. 1998. Tumor necrosis factor-alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease. J. Clin. Invest. 102: 1882-1891.
42. Taylor, P. A., M. J. Ehrhardt, C. J. Lees, A. Panoskaltsis-Mortari, A. M. Krieg, A. H. Sharpe, W. J. Murphy, J. S. Serody, H. Hemmi, S. Akira, et al. 2008. TLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejection. Blood 112: 3508-3516.
43. Kalinski, P., C. M. Hilkens, A. Snijders, F. G. Snijdewint, and M. L. Kapsenberg. 1997. IL-12-deficient dendritic cells, generated in the presence of prostaglandin E2, promote type 2 cytokine production in maturing human naive T helper cells. J. Immunol. 159: 28-35.
44. Hossain, M. S., D. L. Jaye, B. P. Pollack, A. B. Farris, M. L. Tselanyane, E. David, J. D. Roback, A. T. Gewirtz, and E. K. Waller. 2011. Flagellin, a TLR5 agonist, reduces graft-versus-host disease in allogeneic hematopoietic stem cell transplantation recipients while enhancing antiviral immunity. J. Immunol. 187: 5130-5140.
45. Uematsu, S., M. H. Jang, N. Chevrier, Z. Guo, Y Kumagai, M. Yamamoto, H. Kato, N. Sougawa, H. Matsui, H. Kuwata, et al. 2006. Detection of pathogenic intestinal bacteria by Toll-like receptor 5 on intestinal CD11c+ lamina propria cells. Nat. Immunol. 7: 868-874.